🔗 Visit the ClinicalTrials.gov page for NCT01149122
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. | Lancet Oncol | 2011 | 2.89 |
| 2 | Trial watch: Chemotherapy with immunogenic cell death inducers. | Oncoimmunology | 2012 | 1.33 |
| 3 | Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer. | Transl Oncol | 2015 | 0.80 |
| 4 | Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer. | BMC Cancer | 2015 | 0.76 |